Hofseth BioCare ASA Explores Unsecured Bond Opportunities

Hofseth BioCare ASA Explores Unsecured Bond Opportunities

Hofseth BioCare ASA is taking significant steps to bolster its financial strategy by exploring the issuance of CHF-denominated unsecured bonds. With an anticipated volume of up to CHF 8 million, the company is aiming to attract investors primarily in Switzerland and Liechtenstein. This move reflects Hofseth's ambition to broaden its investment base and enhance its operational capabilities.

Engagement with Investors

The company has enlisted the expertise of Novum Asset Management AG to facilitate this process effectively. Not only does Hofseth aim to attract investors from Switzerland and Liechtenstein, but it also plans to engage directly with potential investors in Norway. This dual strategy marks an important pivot in their financial outreach.

Expectations for the Bond Issuance

The proposed bonds will have a tenor of three years, which aligns with the company’s long-term strategy for sustainable growth. While specific details about the issuance and the associated terms are still to be made public, stakeholders can expect to receive more comprehensive information as this process progresses.

Contact Information

For anyone interested in learning more about this initiative, direct inquiries can be directed to Jon Olav Ødegård, the CEO of Hofseth BioCare, at +47 936 32 966 or via email at joo@hofsethbiocare.no.

About Hofseth BioCare ASA

Hofseth BioCare ASA is driven by a commitment to health, sustainability, and the effective use of natural resources. As a pioneer in the consumer and pet health sectors, Hofseth has positioned itself uniquely within the salmon industry by upcycling by-products into health-enhancing ingredients. This innovative practice not only addresses waste but also empowers their product range.

Innovative Health Products

The company produces several patented health products, including ProGo®, OmeGo®, and CalGo® / NT-II™. ProGo® is enriched with bioactive peptides that amplify iron metabolism, promoting energy and vitality. Similarly, OmeGo® offers a comprehensive salmon oil rich in essential fatty acids known to bolster immune health and respiratory conditions. Meanwhile, CalGo® contributes to bone and joint health, ideal for supporting active lifestyles and healthy aging.

Research and Collaborations

Hofseth BioCare is at the forefront of scientific research, forming key academic partnerships to validate their health product claims. These collaborations have led to breakthrough discoveries in health benefits, significantly enhancing the company's reputation in the field. Additionally, the company has launched HBC Immunology (HBCI), a spin-off that is channeling funds into new therapeutic studies, including promising approaches for prostate and ovarian cancers.

Future Directions

HBCI is exploring exciting new treatments, including a potential oral therapy aimed at reducing steroid use for asthma patients. Hofseth's commitment to innovation and health continues to thrive, making it a noteworthy player in both consumer and therapeutic health sectors.

Frequently Asked Questions

What is Hofseth BioCare ASA planning with the bonds?

Hofseth is exploring the issuance of unsecured bonds to enhance its financial capabilities and expand its investor base.

How much do they plan to raise through the bond issuance?

The company aims to raise up to CHF 8 million.

Who is assisting Hofseth in this process?

Novum Asset Management AG has been hired to facilitate the bond issuance.

What are some of Hofseth's key products?

Some of their key offerings include ProGo®, OmeGo®, and CalGo® / NT-II™, which support various health benefits.

What is the goal of HBC Immunology?

HBC Immunology focuses on developing therapeutics, including cancer treatments and alternatives for asthma management.

About The Author

Hello, I'm Thomas Cooper, a financial expert and writer passionate about helping people understand and navigate the financial world. Having a solid financial background and a lot of experience, my area of expertise is simplifying difficult financial ideas into useful, understandable guidance. My goal with my writings and blog entries is to provide you the information and resources you need to make wise financial choices.

I am thrilled to contribute my ideas and engage with a lively investor community at Investors Hangout, where I recently joined the team. My mission is to make finance interesting and approachable so you may take charge of your financial future. I appreciate you coming along on this path to success and financial knowledge.

Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.